Age and leukocyte count as prognostic factors on acute lymphoblastic leukemia: hgmlal07 cohort

Article Sidebar

PDF (Español (España)) HTML (Español (España))
Published: Jul 27, 2016
DOI: https://doi.org/10.21676/2389783X.1720
Keywords:
Age of Onset, Disease-Free Survival, Leukocyte Count, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis

Main Article Content

Washington Ladines-Castro
Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México
Adrián Santoyo-Sánchez
Unidad de Medicina Experimental, Universidad Nacional Autónoma de México. Ciudad de México
Etta Rozen-Fuller
Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México
Irma Olarte-Carrillo
Laboratorio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México
Adolfo Martínez-Tovar
Laboratorio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México
Humberto Castellanos-Sinco
Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México
Juan Collazo-Jaloma
Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México
Christian Omar Ramos-Peñafiel
Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México – México / Departamento de Hematología, Hospital de Alta Especialidad Bicentenario del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado.

Abstract

In order to establish the cutoff with prognostic implications for white blood cell count and age at diagnosis in adults with acute lymphoblastic leukemia (ALL), we conducted an observational, descriptive and analytical study nested in a retrospective cohort of patients with ALL treated by institutional protocol HGMLAL07 during 2007-2014. We study 255 patients, the 52.9% (n=135) were female and 47.1% (n=120) were male. The mean age was 31 (16-80) years-old. The disease-free survival (DFS) decreases in both genders after 20 years-old (p = 0.001). Leukocyte count average was 56.1 x 109/L (0.1-850 x 109/L). DFS decreases significantly from an equal or greater leukocyte count of 20 x 109/L (p<0.05). With this results, we can conclude that use foreign cutoff for age and leukocyte count could determine a bad prognosis stratification and a consequent suboptimal treatment.

Downloads

Download data is not yet available.

Article Details

How to Cite
Ladines-Castro, W., Santoyo-Sánchez, A., Rozen-Fuller, E., Olarte-Carrillo, I., Martínez-Tovar, A., Castellanos-Sinco, H., … Ramos-Peñafiel, C. O. (2016). Age and leukocyte count as prognostic factors on acute lymphoblastic leukemia: hgmlal07 cohort. Duazary, 13(2), 142–148. https://doi.org/10.21676/2389783X.1720
Issue
Vol. 13 No. 2 (2016): (July – December)
Section
Articles of scientific and technological research 
Commercial use of the original work or of possible derivative works is not allowed, the distribution of which must be done with a license equal to that which regulates the original work.
 
 
 
 
Author Biographies

Washington Ladines-Castro, Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México

Médico Cirujano, Residente de Hematología de tercer año

Adrián Santoyo-Sánchez, Unidad de Medicina Experimental, Universidad Nacional Autónoma de México. Ciudad de México

Médico Pasante de Servicio Social

Etta Rozen-Fuller, Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México

Médico especialista en Hematología

Irma Olarte-Carrillo, Laboratorio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México

Doctor en Ciencias Biológicas y de la Salud

Adolfo Martínez-Tovar, Laboratorio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México

Doctor en Genética y Biología Molecular

Humberto Castellanos-Sinco, Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México

Médico especialista en Hematología

Juan Collazo-Jaloma, Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México

Jefe de Servicio, Médico especialista en Hematología

Christian Omar Ramos-Peñafiel, Servicio de Hematología, Hospital General de México “Dr. Eduardo Liceaga”. Ciudad de México – México / Departamento de Hematología, Hospital de Alta Especialidad Bicentenario del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado.

Jefe del área clínica. Médico especialista en Hematología

References

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon: International Agency for Research on Cancer Press; 2008.

Nath S V, Nicholson I, Tapp H, Zola H, Zannettino ACW, Revesz T. Reticulin fibres anchor leukaemic blasts in the marrow of patients with acute lymphoblastic leukaemia. Med Hypotheses. 2011;77(3):333–5.

Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):64–75.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531–41.

Sanford DS, Kantarjian H, O’Brien S, Jabbour E, Cortes J, Ravandi F. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015;15(4):365–73.

Portell CA, Advani AS. Antibody therapy for acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2012;7(2):153–9.

Ai J, Advani A. Current status of antibody therapy in ALL. Br J Haematol. 2015;168(4):471–80.

Pui C-H, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551–65.

Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98(11):1702–10.

Hoelzer D, Thiel E, Löffler H, Ganser A, Heimpel H, Büchner T, et al. Risk groups in adult acute lymphoblastic leukemia. Haematol Blood Transfus. 1987;30:104–10.

Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–7.

Wang H, Chen X-Q, Geng Q-R, Liu P-P, Lin G-N, Xia Z-J, et al. Induction therapy using the MRC UKALLXII/ECOG E2993 protocol in Chinese adults with acute lymphoblastic leukemia. Int J Hematol. 2011;94(2):163–8.

Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. American Society of Hematology; 1995;85(8):2025–37.

Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99(3):863–71.

Ramos C, Rozen E, León M, Martínez T A, Olarte I, Catellanos H, et al. [Results of treatment of acute lymphoblastic leukemia in two cohorts of Mexican patients]. Rev Med Chil. 2011;139(9):1135–42.

Jaso J, Thomas DA, Cunningham K, Jorgensen JL, Kantarjian HM, Medeiros LJ, et al. Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer. 2011;117(17):4009–17.

Jiménez-Morales S, Miranda-Peralta E, Saldaña-Alvarez Y, Perez-Vera P, Paredes-Aguilera R, Rivera-Luna R, et al. BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients. Leuk Res. 2008;32(10):1518–22.

Ganzel C, Rowe JM. Prognostic factors in adult acute leukemia. Hematol Oncol Clin North Am. 2011;25(6):1163–87.

Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012;119(1):34–43.

Sant M, Allemani C, Tereanu C, Angelis R De, Capocaccia R, Marcos-gragera R, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–34.

De França Azevedo I, da Silva Júnior RMP, de Vasconcelos AVM, das Neves WB, de Barros Correia Melo FC, Melo RAM. Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia. Rev Bras Hematol Hemoter. 36(5):351–5.

Hoelzer D, Thiel E, Löffler H, Büchner T, Ganser A, Heil G, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71(1):123–31.

Gokbuget N, Kneba M, Raff T, Trautmann H, Bartram C-R, Arnold R, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. American Society of Hematology. 2012;120(9):1868–76.

Van Zant G, Liang Y. Concise Review: Hematopoietic Stem Cell Aging, Life Span, and Transplantation. Stem Cells Transl Med. 2012;1(9):651–7.